AstraZeneca Pharma India has suffered Rs 33 crore loss during the fourth quarter ended March 31 compared with Rs 14.93 crore profit in the corresponding quarter of previous year.
The company's revenues saw a decline by 40.21 per cent to Rs 91.78 crore for the quarter against Rs 153.52 crore in the same period previous year.
According to analysts, the pharma multinational suffered losses due to a voluntary recall of sterile products.
For the whole financial year (2011-12), the company profits was down 69.18 per cent to Rs 19.76 crore against Rs 64.12 crore in the previous fiscal.
Revenues were also down 10.56 per cent at Rs 531.52 crore for the year against Rs 594.30 crore recorded in the previous year.
The company in a release to exchanges has said that the board of directors at its meeting held on May 11 has recommended a dividend of Rs 3.50 an equity share of face value of Rs 2 each (175 per cent) for the financial year ended March 31, subject to the approval of the shareholders at the ensuing annual general meeting.
The Board also approved the appointment of Mr Pawan Singhal as the Vice-President - Legal and Secretarial of the company, and designated him as the Compliance Officer.